Lynette M. Sholl
Cedars-Sinai Medical Center(US)Brigham and Women's Hospital(US)Harvard University(US)Hospital Universitario La Paz(ES)Cancer Clinic(US)Dana-Farber Brigham Cancer Center(US)Universidad Autónoma de Madrid(ES)Zhejiang University(CN)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics, RNA modifications and cancer, Cancer Immunotherapy and Biomarkers, Lung Cancer Research Studies
Most-Cited Works
- → STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma(2018)1,562 cited
- → PD-L1 as a biomarker of response to immune-checkpoint inhibitors(2021)1,497 cited
- → The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015(2021)1,374 cited
- → Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors(2013)1,232 cited
- → Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology(2018)901 cited
- → Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors(2018)